Cardior Pharmaceuticals GmbH has published results of preclinical in vivo studies in Nature Communications showing that its lead compound, CDR132L, can significantly improve the functioning of pathologically altered hearts.
How to increase the social benefit of European research funding? Members of the ASTP’s National Associations’ Advisory Committee (NAAC) recently met representatives of the European Commission (EC) in Brussels to discuss this question.
We would like to thank all our clients, colleagues and partners in technology transfer, research and industry for the enjoyable and productive collaboration over the past year.
A research team at the German Center for Neurodegenerative Diseases (DZNE) has received the ‘Hugo Junkers Award for Research and Innovation from Saxony-Anhalt 2019’.
Ascenion GmbH, technology transfer partner of the Max Delbrück Center for Molecular Medicine (MDC), has supported the conclusion of an agreement between the MDC and Fate Therapeutics, Inc.
Don’t miss your chance to secure a spot at next year’s BioVaria, 27 – 28 April 2020 in Munich! Application for European startups is now open until 14t…